NCT04177004 2026-04-15
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
City of Hope Medical Center
Phase 1 Suspended
Clinical Trials
18 trialsNCT01375829 2026-04-13
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05088356 2026-04-08
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1 Recruiting
NCT02389309 2026-03-09
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT07162038 2026-01-23
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT01087554 2026-01-16
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06528301 2026-01-12
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
Phase 1 Recruiting
NCT01282697 2025-12-22
RAPIRI
University Hospital, Strasbourg, France
Phase 1 Completed
NCT05508906 2025-10-22
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1 Recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06743503 2025-09-18
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Nanjing IASO Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT06287944 2025-07-29
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Recruiting
NCT04473911 2025-07-20
Haplo Peripheral Blood Sct In GVHD Prevention
Massachusetts General Hospital
Phase 1 Completed
NCT02517918 2025-06-08
METZOLIMOS
Institut Bergonié
Phase 1 Completed
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting